Cyclo Therapeutics, Inc. (CYTH)

Market Cap	29.73M
Revenue (ttm)	908,499
Net Income (ttm)	-18.87M
Shares Out	19.31M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17
Open	1.51
Previous Close	1.52
Day's Range	1.42 - 1.68
52-Week Range	0.67 - 2.57
Beta	-0.41
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 10, 2023

About CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTH

Financial Performance

In 2022, CYTH's revenue was $1.38 million, a decrease of -13.24% compared to the previous year's $1.59 million. Losses were -$15.45 million, 8.15% more than in 2021.